LEN
34
-2
HBAN
54
-5
CHRW
48
-2
EA
47
3
AA
61
4
MTCH
68
15
NTRS
52
-12
PNW
55
2
SNA
55
-13
KHC
36
-2
GT
43
-2
AKAM
40
3
TMO
42
-4
BMY
37
-4
AMZN
52
-9
PCG
50
2
ABT
39
3
APD
54
2
HAL
46
-4
FITB
58
-10
LEN
34
-2
HBAN
54
-5
CHRW
48
-2
EA
47
3
AA
61
4
MTCH
68
15
NTRS
52
-12
PNW
55
2
SNA
55
-13
KHC
36
-2
GT
43
-2
AKAM
40
3
TMO
42
-4
BMY
37
-4
AMZN
52
-9
PCG
50
2
ABT
39
3
APD
54
2
HAL
46
-4
FITB
58
-10
Financhill
Back

Lixte Biotechnology Holdings 10K Form

Buy
63

LIXT
Lixte Biotechnology Holdings

Last Price:
$4.04
Seasonality Move:
-1.61%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive LIXT News And Ratings

See the #1 stock for the next 7 days that we like better than LIXT

LIXT Financial Statistics

Sales & Book Value

Annual Sales: $200K
Cash Flow: $-568.5K
Price / Cash Flow: 0
Annual Sales: $-0.87
Price / Book: 0

Profitability

EPS (TTM): -1.45000
Net Income (TTM): $-3.3M
Gross Margin: $0
Return on Equity: 0%
Return on Assets: 0%

Lixte Biotechnology Holdings Earnings Forecast

Key Lixte Biotechnology Holdings Financial Ratios

  • The Selling, General & Administrative Expenses for LIXT have been equal to 377.22% of Gross Profit Margin.
  • Per Share Earnings over the last 20 years have been positive in 9 years.

Lixte Biotechnology Holdings Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: LIXT
Website: lixte.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

LIXT Technical Analysis vs Fundamental Analysis

Buy
63
Lixte Biotechnology Holdings (LIXT) is a Buy

Is Lixte Biotechnology Holdings a Buy or a Sell?